fashion -WSS

fashion

author：fashion 2025-09-29 12:29:55 - browse：1572

A judge ruled that Welsh Carson won't have to face antitrust allegations about its anesthesiology practice. Adobe

Welsh, Carson, Anderson & Stowe has wiggled out of the grasp of the Federal Trade Commission, but the private equity firm’s anesthesia company, U.S. Anesthesia Partners, still must face the agency’s antitrust case, a judge ruled last week.

The FTC alleged last year that the anesthesiology network monopolized markets in Texas to drive up prices, but took the unusual step of attaching Welsh Carson as a defendant with USAP. Dismissing Welsh Carson from the case was a victory for the private equity firm and, more broadly, other firms worried that the Biden administration would try to hold them responsible for anything their portfolio companies do.

But the allegations against USAP didn’t disappear, which will keep up scrutiny on companies that have made a push to acquire numerous physician groups.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Ionis drug prevents swelling attacks due to hereditary angioedema

WSS

Mitch McConnell episode has important public health takeaway

BMI, flaws aside, is found to be useful estimate of body fat in youth

NIH launches clinical trials and new research office for long Covid

Ionis drug prevents swelling attacks due to hereditary angioedema

Woman returns to dialysis after doctors remove transplanted pig kidney

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

leisure time

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

explore

Hepatitis C has a cure — but many Americans still lack access to it

Sage hopes for a blockbuster in antidepressant now before FDA

Moonlake's readout produced a cash windfall. Risks remain

Letters to First Opinion on caregivers, digital health, and more

New air purifier tech could be key to improving indoor air quality

‘Oppenheimer’ and the risks of AI in health care

Continuity nursing helped my family in our darkest PICU moments

Scientists inch closer to single

At least 13 dead in Texas as scorching temps continue

Wildfire pollution widens asthma inequities on Long Island

entertainment

‘Oppenheimer’ and the risks of AI in health care

At ASCO, AstraZeneca reports strong data for breast cancer drug

BMI, flaws aside, is found to be useful estimate of body fat in youth

Cord blood banking comes at a high cost to babies

Ultragenyx gene therapy for rare liver ailment succeeds in late

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

entertainment

hotspot

hotspot

focus